COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Novo Nordisk A/S: Articles of Association for Novo Nordisk A/S24/04/2018
-   
  Novo Nordisk A/S - Reduction of the share capital24/04/2018
-   
  Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive Advisory Board24/04/2018
-   
  FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares24/04/2018
-   
  Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference24/04/2018
-   
  Progyny Launches “This is Infertility” Podcast24/04/2018
-   
  Pediapharm to Present at Bloom Burton & Co. Healthcare Investor Conference24/04/2018
-   
  Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th24/04/2018
-   
  Tabula Rasa HealthCare Launches its Optimized Opioid Solution™ to Predict and Prevent Unintentional Opioid Abuse24/04/2018
-   
  Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 201824/04/2018
-   
  Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine24/04/2018
-   
  Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina Lineberger Advanced Cellular Therapeutics Facility for X-Series™ Products That Provide Automated, Closed System Cellular Processing24/04/2018
-   
  Yield10 Bioscience Announces Plans for its 2018 Field Test Program24/04/2018
-   
  Advanced Proteome Therapeutics Announces Appointment of Scientific Advisory Board Members24/04/2018
-   
  Tower One Receives Warrant Exercise Proceeds of $2,166,300.0024/04/2018
-   
  MJ Biotech Inc. Current & Future Business Operations24/04/2018
-   
  Finalists Announced for 2018 Diabetes Innovation Challenge24/04/2018
-   
  The Epilepsy Foundation Launches a New Research Study to Find Biomarkers for Treatment of Focal Seizures in People with Epilepsy24/04/2018
-   
  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting24/04/2018
Pages